Last reviewed · How we verify
Trivalent-Tasmania influenza vaccine
Trivalent-Tasmania influenza vaccine is a Biologic drug developed by Sanofi Pasteur, a Sanofi Company. It is currently in Phase 1 development.
At a glance
| Generic name | Trivalent-Tasmania influenza vaccine |
|---|---|
| Sponsor | Sanofi Pasteur, a Sanofi Company |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Trivalent-Tasmania influenza vaccine CI brief — competitive landscape report
- Trivalent-Tasmania influenza vaccine updates RSS · CI watch RSS
- Sanofi Pasteur, a Sanofi Company portfolio CI
Frequently asked questions about Trivalent-Tasmania influenza vaccine
What is Trivalent-Tasmania influenza vaccine?
Trivalent-Tasmania influenza vaccine is a Biologic drug developed by Sanofi Pasteur, a Sanofi Company.
Who makes Trivalent-Tasmania influenza vaccine?
Trivalent-Tasmania influenza vaccine is developed by Sanofi Pasteur, a Sanofi Company (see full Sanofi Pasteur, a Sanofi Company pipeline at /company/sanofi).
What development phase is Trivalent-Tasmania influenza vaccine in?
Trivalent-Tasmania influenza vaccine is in Phase 1.